* Oragenics (NYSE:OGEN [https://seekingalpha.com/symbol/OGEN]) on Tuesday said that it has collaboreted with Receptor.AI, an artificial intelligence-driven drug profiling company, to accelerate the development of its neurological drug pipeline.
* The collaboration aims to expand Oragenics’ pharmaceutical pipeline by using advanced AI to identify optimal receptor binding profiles for newly acquired compounds.
* This will support the company's research into treatments for neurological and psychiatric conditions, including Alzheimer’s, Parkinson’s, PTSD, and anxiety disorders.
* OGEN +2.30% premarket to $1.33.
* Source: Press Release [https://seekingalpha.com/pr/20256992-oragenics-announces-strategic-partnership-with-receptor-ai-to-accelerate-pipeline-development]
MORE ON ORAGENICS
* Seeking Alpha’s Quant Rating on Oragenics [https://seekingalpha.com/symbol/OGEN/ratings/quant-ratings]
* Historical earnings data for Oragenics [https://seekingalpha.com/symbol/OGEN/earnings]
* Financial information for Oragenics [https://seekingalpha.com/symbol/OGEN/income-statement]
Oragenics announces partnership with Receptor.AI
Published 1 month ago
Oct 7, 2025 at 12:41 PM
Positive
Auto